RESUMEN
Canine Parvovirus (CPV) is a very contagious and virulent viral disease affecting domestic dogs all over the world causing high morbidity and mortality in dogs, especially puppies. This study aimed at determining the seropositivity of IgG antibodies against CPV in vaccinated and unvaccinated dogs and to evaluate the immune status of dogs presented in Abeokuta. Forty-eight dogs were enrolled in this study. These dogs were presented at random for treatment, routine checkup, and vaccination at the State Veterinary Hospital and Veterinary Teaching Hospital all in Abeokuta. All the dogs were fully maintained under domestic setting. Selection for study was done based on thorough examination of the dogs and their medical records. The clients were informed of the nature of the investigation. Blood samples were collected and analyzed for anti-CPV-IgG. In principle, protective immunity correlates with high antibody titers and this was determined using a commercially available immunocomb® test kit for anti-CPV IgG antibody. Of 48 dogs sampled, 38 (79.2%) had high level of anti-CPV antibody titer and 10 (20.8%) had low level of anti-CPV antibody titer. Twenty six (54.2%) were males while 22 (45.8%) were females. Forty-five (93.75%) dogs were exotic breeds while 3 (6.25%) dogs were mongrels. Thirty (62.5%) of the dogs were less than one year old and the age range of all dogs sampled was between 7 weeks and 7 years. There was no significant difference (P > 0.05) between sex and the level of immunity but significant differences (P < 0.05) were observed between ages of dogs, breeds, post-vaccination period, and the level of immunity. In conclusion, this study has further confirmed the presence of IgG antibodies against canine parvovirus among dogs in Abeokuta, Nigeria. Of all variables evaluated, ages of dogs, breeds and post-vaccination period were the main correlates of the level of immunity to CPV. This study also showed agreement with previous studies in the diagnostic value of using the immunoblot ELISA assay for the rapid detection of anti-CPV IgG antibody.